O	O	O	0	6	Potent	Potent	B-NP	JJ	O	3	AMOD	O
O	O	O	7	10	and	and	I-NP	CC	O	3	AMOD	O
O	O	O	11	17	stable	stable	I-NP	JJ	O	4	NMOD	O
O	O	O	18	29	attenuation	attenuation	I-NP	NN	O	0	ROOT	O
O	O	O	30	32	of	of	B-PP	IN	O	4	NMOD	O
O	O	O	33	37	live	live	B-NP	JJ	O	10	NMOD	O
O	O	O	37	38	-	-	I-NP	HYPH	O	10	P	O
O	O	O	38	41	HIV	HIV	I-NP	NN	O	10	NMOD	O
O	O	O	41	42	-	-	B-NP	HYPH	O	10	P	O
O	O	O	42	43	1	1	I-NP	CD	O	5	PMOD	O
O	O	O	44	46	by	by	B-PP	IN	O	4	NMOD	O
O	O	O	47	51	gain	gain	B-NP	NN	O	32	NMOD	O
O	O	O	52	54	of	of	B-PP	IN	O	12	NMOD	O
O	O	O	55	56	a	a	B-NP	DT	O	15	NMOD	O
O	O	O	57	68	proteolysis	proteolysis	I-NP	NN	O	18	NMOD	O
O	O	O	68	69	-	-	B-NP	HYPH	O	18	P	O
O	O	O	69	78	resistant	resistant	I-NP	JJ	O	18	NMOD	O
O	O	O	79	88	inhibitor	inhibitor	I-NP	NN	O	13	PMOD	O
O	O	O	89	91	of	of	B-PP	IN	O	18	NMOD	O
T8	B-Entity	B-Entity	92	94	NF	NF	B-NP	NN	B-protein	22	NMOD	B-protein
T8	I-Entity	I-Entity	94	95	-	-	B-NP	HYPH	I-protein	22	NMOD	I-protein
T8	I-Entity	I-Entity	95	101	kappaB	kappaB	I-NP	NN	I-protein	19	PMOD	I-protein
O	O	O	102	103	(	(	O	(	O	29	DEP	O
T1	B-Protein	B-Protein	103	110	IkappaB	IkappaB	B-NP	NN	B-protein	28	NMOD	B-protein
T1	I-Protein	I-Protein	110	111	-	-	B-NP	HYPH	O	28	P	O
T1	I-Protein	I-Protein	111	119	alphaS32	alphaS32	I-NP	NN	B-protein	28	NMOD	B-protein
O	O	O	119	120	/	/	I-NP	SYM	I-protein	28	NMOD	I-protein
O	O	O	120	123	36A	36A	I-NP	NN	I-protein	29	DEP	I-protein
O	O	O	123	124	)	)	O	)	O	18	NMOD	O
O	O	O	125	128	and	and	O	CC	O	32	NMOD	O
O	O	O	129	132	the	the	B-NP	DT	O	32	NMOD	O
O	O	O	133	145	implications	implication	I-NP	NNS	O	11	PMOD	O
O	O	O	146	149	for	for	B-PP	IN	O	32	NMOD	O
O	O	O	150	157	vaccine	vaccine	B-NP	NN	O	35	NMOD	O
O	O	O	158	169	development	development	I-NP	NN	O	33	PMOD	O
O	O	O	169	170	.	.	O	.	O	4	P	O

O	O	O	172	176	Live	Live	B-NP	NN	O	0	ROOT	O
O	O	O	176	177	-	-	O	HYPH	O	1	P	O
O	O	O	177	187	attenuated	attenuate	B-VP	VBN	O	1	NMOD	O
O	O	O	188	193	human	human	B-NP	JJ	O	6	NMOD	O
O	O	O	194	210	immunodeficiency	immunodeficiency	I-NP	NN	O	6	NMOD	O
O	O	O	211	218	viruses	virus	I-NP	NNS	O	10	SUB	O
O	O	O	219	220	(	(	O	(	O	9	DEP	O
O	O	O	220	224	HIVs	HIV	B-NP	NNS	O	9	DEP	O
O	O	O	224	225	)	)	O	)	O	6	NMOD	O
O	O	O	226	229	are	be	B-VP	VBP	O	3	VMOD	O
O	O	O	230	240	candidates	candidate	B-NP	NNS	O	10	PRD	O
O	O	O	241	244	for	for	B-PP	IN	O	11	NMOD	O
O	O	O	245	253	Acquired	Acquire	B-NP	VBN	O	15	NMOD	O
O	O	O	254	270	Immunodeficiency	Immunodeficiency	I-NP	NN	O	15	NMOD	O
O	O	O	271	279	Syndrome	Syndrome	I-NP	NN	O	19	NMOD	O
O	O	O	280	281	(	(	O	(	O	18	DEP	O
O	O	O	281	285	AIDS	AIDS	B-NP	NN	O	18	DEP	O
O	O	O	285	286	)	)	O	)	O	15	NMOD	O
O	O	O	287	294	vaccine	vaccine	B-NP	NN	O	12	PMOD	O
O	O	O	294	295	.	.	O	.	O	1	P	O

O	O	O	296	301	Based	Base	B-PP	VBN	O	15	NMOD	O
O	O	O	302	304	on	on	B-PP	IN	O	1	PMOD	O
O	O	O	305	308	the	the	B-NP	DT	O	6	NMOD	O
O	O	O	309	315	simian	simian	I-NP	JJ	O	6	NMOD	O
O	O	O	316	332	immunodeficiency	immunodeficiency	I-NP	NN	O	6	NMOD	O
O	O	O	333	338	virus	virus	I-NP	NN	O	2	PMOD	O
O	O	O	339	340	(	(	O	(	O	9	DEP	O
O	O	O	340	343	SIV	SIV	B-NP	NN	O	9	DEP	O
O	O	O	343	344	)	)	O	)	O	6	NMOD	O
O	O	O	345	350	model	model	B-NP	NN	O	6	NMOD	O
O	O	O	351	354	for	for	B-PP	IN	O	6	NMOD	O
O	O	O	355	359	AIDS	AIDS	B-NP	NN	O	11	PMOD	O
O	O	O	359	360	,	,	O	,	O	15	P	O
O	O	O	361	365	loss	loss	B-NP	NN	O	15	NMOD	O
O	O	O	365	366	-	-	B-NP	HYPH	O	32	SUB	O
O	O	O	366	368	of	of	B-PP	IN	O	15	NMOD	O
O	O	O	368	369	-	-	B-NP	HYPH	O	16	PMOD	O
O	O	O	369	377	function	function	I-NP	NN	O	17	NMOD	O
O	O	O	378	379	(	(	O	(	O	31	DEP	O
O	O	O	379	380	e	e	B-NP	NN	O	22	NMOD	O
O	O	O	380	381	.	.	O	.	O	20	P	O
O	O	O	381	382	g	g	B-NP	NN	O	24	NMOD	O
O	O	O	382	383	.	.	O	.	O	22	P	O
O	O	O	384	392	deletion	deletion	B-NP	NN	O	31	DEP	O
O	O	O	393	395	of	of	B-PP	IN	O	24	NMOD	O
O	O	O	396	405	accessory	accessory	B-NP	JJ	B-DNA	27	NMOD	B-DNA
O	O	O	406	411	genes	gene	I-NP	NNS	I-DNA	25	PMOD	I-DNA
O	O	O	412	416	such	such	B-PP	JJ	O	29	PMOD	O
O	O	O	417	419	as	as	I-PP	IN	O	27	NMOD	O
T2	B-Protein	B-Protein	420	423	nef	nef	B-NP	NN	B-protein	29	PMOD	B-protein
O	O	O	423	424	)	)	O	)	O	18	NMOD	O
O	O	O	425	428	has	have	B-VP	VBZ	O	0	ROOT	O
O	O	O	429	433	been	be	I-VP	VBN	O	32	VC	O
O	O	O	434	443	forwarded	forward	I-VP	VBN	O	33	VC	O
O	O	O	444	446	as	as	B-PP	IN	O	34	VMOD	O
O	O	O	447	448	a	a	B-NP	DT	O	38	NMOD	O
O	O	O	449	456	primary	primary	I-NP	JJ	O	38	NMOD	O
O	O	O	457	465	approach	approach	I-NP	NN	O	35	PMOD	O
O	O	O	466	469	for	for	B-PP	IN	O	38	NMOD	O
O	O	O	470	478	creating	create	B-VP	VBG	O	39	PMOD	O
O	O	O	479	488	enfeebled	enfeeble	I-VP	VBN	O	52	NMOD	O
O	O	O	488	489	,	,	O	,	O	52	P	O
O	O	O	490	493	but	but	O	CC	O	52	NMOD	O
O	O	O	494	505	replication	replication	B-NP	NN	O	52	NMOD	O
O	O	O	505	506	-	-	B-NP	HYPH	O	44	P	O
O	O	O	506	515	competent	competent	I-NP	JJ	O	44	AMOD	O
O	O	O	515	516	,	,	I-NP	,	O	52	P	O
O	O	O	517	520	HIV	HIV	I-NP	NN	O	52	NMOD	O
O	O	O	520	521	-	-	I-NP	HYPH	O	52	NMOD	O
O	O	O	521	522	1	1	I-NP	CD	O	52	NMOD	O
O	O	O	522	523	/	/	I-NP	SYM	O	52	NMOD	O
O	O	O	523	526	SIV	SIV	I-NP	NN	O	40	OBJ	O
O	O	O	526	527	.	.	O	.	O	32	P	O

O	O	O	528	539	Regrettably	Regrettably	B-ADVP	RB	O	5	VMOD	O
O	O	O	539	540	,	,	O	,	O	5	P	O
O	O	O	541	547	recent	recent	B-NP	JJ	O	4	NMOD	O
O	O	O	548	556	evidence	evidence	I-NP	NN	O	5	SUB	O
O	O	O	557	565	suggests	suggest	B-VP	VBZ	O	0	ROOT	O
O	O	O	566	570	that	that	B-SBAR	IN	O	5	VMOD	O
O	O	O	571	575	loss	loss	B-NP	NN	O	13	SUB	O
O	O	O	575	576	-	-	B-NP	HYPH	O	7	P	O
O	O	O	576	578	of	of	B-PP	IN	O	7	NMOD	O
O	O	O	578	579	-	-	B-NP	HYPH	O	11	NMOD	O
O	O	O	579	587	function	function	I-NP	NN	O	9	PMOD	O
O	O	O	588	593	alone	alone	B-ADVP	RB	O	7	NMOD	O
O	O	O	594	596	is	be	B-VP	VBZ	O	6	SBAR	O
O	O	O	597	600	not	not	O	RB	O	13	VMOD	O
O	O	O	601	607	always	always	B-ADVP	RB	O	13	VMOD	O
O	O	O	608	618	sufficient	sufficient	B-ADJP	JJ	O	13	PRD	O
O	O	O	619	621	to	to	B-VP	TO	O	18	VMOD	O
O	O	O	622	629	prevent	prevent	I-VP	VB	O	16	AMOD	O
O	O	O	630	633	the	the	B-NP	DT	O	20	NMOD	O
O	O	O	634	643	emergence	emergence	I-NP	NN	O	18	OBJ	O
O	O	O	644	646	of	of	B-PP	IN	O	20	NMOD	O
O	O	O	647	655	virulent	virulent	B-NP	JJ	B-protein	23	NMOD	B-protein
O	O	O	656	663	mutants	mutant	I-NP	NNS	I-protein	21	PMOD	I-protein
O	O	O	663	664	.	.	O	.	O	5	P	O

O	O	O	665	668	New	New	B-NP	JJ	O	2	NMOD	O
O	O	O	669	679	strategies	strategy	I-NP	NNS	O	14	SUB	O
O	O	O	680	684	that	that	B-NP	WDT	O	2	NMOD	O
O	O	O	685	694	attenuate	attenuate	B-VP	VBP	O	3	SBAR	O
O	O	O	695	698	via	via	B-PP	IN	O	4	VMOD	O
O	O	O	699	709	mechanisms	mechanism	B-NP	NNS	O	5	PMOD	O
O	O	O	710	718	distinct	distinct	B-ADJP	JJ	O	6	NMOD	O
O	O	O	719	723	from	from	B-PP	IN	O	7	AMOD	O
O	O	O	724	728	loss	loss	B-NP	NN	O	8	PMOD	O
O	O	O	728	729	-	-	B-ADVP	HYPH	O	9	P	O
O	O	O	729	731	of	of	B-PP	IN	O	9	NMOD	O
O	O	O	731	732	-	-	B-NP	HYPH	O	13	NMOD	O
O	O	O	732	740	function	function	I-NP	NN	O	11	PMOD	O
O	O	O	741	744	are	be	B-VP	VBP	O	0	ROOT	O
O	O	O	745	751	needed	need	I-VP	VBN	O	14	VC	O
O	O	O	752	755	for	for	B-PP	IN	O	15	VMOD	O
O	O	O	756	765	enhancing	enhance	B-VP	VBG	O	16	PMOD	O
O	O	O	766	769	the	the	B-NP	DT	O	20	NMOD	O
O	O	O	770	776	safety	safety	I-NP	NN	O	20	NMOD	O
O	O	O	777	786	phenotype	phenotype	I-NP	NN	O	17	OBJ	O
O	O	O	787	789	of	of	B-PP	IN	O	20	NMOD	O
T9	B-Entity	B-Entity	790	795	viral	viral	B-NP	JJ	B-DNA	23	NMOD	B-DNA
T9	I-Entity	I-Entity	796	802	genome	genome	I-NP	NN	I-DNA	21	PMOD	I-DNA
O	O	O	802	803	.	.	O	.	O	14	P	O

O	O	O	804	808	Here	Here	B-ADVP	RB	O	4	VMOD	O
O	O	O	808	809	,	,	O	,	O	4	P	O
O	O	O	810	812	we	we	B-NP	PRP	O	4	SUB	O
O	O	O	813	820	propose	propose	B-VP	VBP	O	0	ROOT	O
O	O	O	821	825	gain	gain	B-NP	NN	O	6	NMOD	O
O	O	O	825	826	-	-	B-NP	HYPH	O	4	VMOD	O
O	O	O	826	828	of	of	B-PP	IN	O	6	NMOD	O
O	O	O	828	829	-	-	B-NP	HYPH	O	9	NMOD	O
O	O	O	829	837	function	function	I-NP	NN	O	7	PMOD	O
O	O	O	838	840	to	to	B-VP	TO	O	11	VMOD	O
O	O	O	841	843	be	be	I-VP	VB	O	6	VMOD	O
O	O	O	844	848	used	use	I-VP	VBN	O	11	VC	O
O	O	O	849	863	simultaneously	simultaneously	B-ADVP	RB	O	12	VMOD	O
O	O	O	864	868	with	with	B-PP	IN	O	12	VMOD	O
O	O	O	869	873	loss	loss	B-NP	NN	O	14	PMOD	O
O	O	O	873	874	-	-	B-NP	HYPH	O	15	P	O
O	O	O	874	876	of	of	B-PP	IN	O	15	NMOD	O
O	O	O	876	877	-	-	B-NP	HYPH	O	19	NMOD	O
O	O	O	877	885	function	function	I-NP	NN	O	17	PMOD	O
O	O	O	886	888	as	as	B-PP	IN	O	12	VMOD	O
O	O	O	889	890	a	a	B-NP	DT	O	23	NMOD	O
O	O	O	891	896	novel	novel	I-NP	JJ	O	23	NMOD	O
O	O	O	897	905	approach	approach	I-NP	NN	O	20	PMOD	O
O	O	O	906	909	for	for	B-PP	IN	O	23	NMOD	O
O	O	O	910	921	attenuating	attenuate	B-VP	VBG	O	24	PMOD	O
O	O	O	922	925	HIV	HIV	B-NP	NN	O	27	NMOD	O
O	O	O	925	926	-	-	B-NP	HYPH	O	25	OBJ	O
O	O	O	926	927	1	1	I-NP	CD	O	27	NMOD	O
O	O	O	927	928	.	.	O	.	O	4	P	O

O	O	O	929	931	We	We	B-NP	PRP	O	2	SUB	O
O	O	O	932	936	have	have	B-VP	VBP	O	0	ROOT	O
O	O	O	937	948	constructed	construct	I-VP	VBN	O	2	VC	O
O	O	O	949	951	an	an	B-NP	DT	O	8	NMOD	O
T10,T11	B-Entity,B-Entity	B-Entity,B-Entity	952	955	HIV	HIV	I-NP	NN	B-DNA	8	NMOD	B-DNA
T10,T11	I-Entity,I-Entity	I-Entity,I-Entity	955	956	-	-	B-NP	HYPH	I-DNA	8	NMOD	I-DNA
T10,T11	I-Entity,I-Entity	I-Entity,I-Entity	956	957	1	1	I-NP	CD	I-DNA	8	NMOD	I-DNA
T10,T11	I-Entity	I-Entity	958	964	genome	genome	I-NP	NN	I-DNA	3	OBJ	I-DNA
T10	I-Entity	I-Entity	965	973	carrying	carry	B-VP	VBG	O	8	NMOD	O
T10	I-Entity	I-Entity	974	977	the	the	B-NP	DT	O	11	NMOD	O
T10,T12	I-Entity,B-Entity	I-Entity,B-Entity	978	982	cDNA	cDNA	I-NP	NN	B-DNA	9	OBJ	B-DNA
O	O	O	983	985	of	of	B-PP	IN	O	11	NMOD	O
O	O	O	986	987	a	a	B-NP	DT	O	21	NMOD	O
O	O	O	988	999	proteolysis	proteolysis	I-NP	NN	B-protein	21	NMOD	B-protein
O	O	O	999	1000	-	-	O	HYPH	I-protein	21	NMOD	I-protein
O	O	O	1000	1009	resistant	resistant	B-NP	JJ	I-protein	18	NMOD	I-protein
O	O	O	1010	1017	nuclear	nuclear	I-NP	JJ	I-protein	18	NMOD	I-protein
O	O	O	1018	1024	factor	factor	I-NP	NN	I-protein	21	NMOD	I-protein
O	O	O	1024	1025	-	-	B-NP	HYPH	O	21	NMOD	O
O	O	O	1025	1031	kappaB	kappaB	I-NP	NN	B-protein	21	NMOD	B-protein
O	O	O	1032	1041	inhibitor	inhibitor	I-NP	NN	O	12	PMOD	O
O	O	O	1042	1043	(	(	O	(	O	28	DEP	O
T3	B-Protein	B-Protein	1043	1050	IkappaB	IkappaB	B-NP	NN	B-protein	27	NMOD	B-protein
T3	I-Protein	I-Protein	1050	1051	-	-	B-NP	HYPH	O	27	P	O
T3	I-Protein	I-Protein	1051	1059	alphaS32	alphaS32	I-NP	NN	B-protein	27	NMOD	B-protein
O	O	O	1059	1060	/	/	I-NP	SYM	O	27	P	O
O	O	O	1060	1063	36A	36A	I-NP	NN	O	28	DEP	O
O	O	O	1063	1064	)	)	O	)	O	21	NMOD	O
O	O	O	1065	1067	in	in	B-PP	IN	O	9	VMOD	O
O	O	O	1068	1071	the	the	B-NP	DT	O	32	NMOD	O
T4	B-Protein	B-Protein	1072	1075	nef	nef	I-NP	NN	B-DNA	32	NMOD	B-DNA
T13	B-Entity	B-Entity	1076	1082	region	region	I-NP	NN	I-DNA	29	PMOD	I-DNA
O	O	O	1082	1083	.	.	O	.	O	2	P	O

O	O	O	1084	1087	HIV	HIV	B-NP	NN	O	9	NMOD	O
O	O	O	1087	1088	-	-	B-NP	HYPH	O	1	P	O
O	O	O	1088	1089	1	1	I-NP	CD	O	1	NMOD	O
O	O	O	1090	1100	expressing	express	I-NP	VBG	O	9	NMOD	O
T5	B-Protein	B-Protein	1101	1108	IkappaB	IkappaB	I-NP	NN	B-protein	9	NMOD	B-protein
T5	I-Protein	I-Protein	1108	1109	-	-	I-NP	HYPH	O	9	NMOD	O
T5	I-Protein	I-Protein	1109	1117	alphaS32	alphaS32	I-NP	NN	B-protein	9	NMOD	B-protein
O	O	O	1117	1118	/	/	B-NP	SYM	I-protein	9	NMOD	I-protein
O	O	O	1118	1121	36A	36A	I-NP	NN	I-protein	12	SUB	I-protein
O	O	O	1122	1126	down	down	B-ADVP	RB	O	11	VMOD	O
O	O	O	1126	1127	-	-	B-NP	HYPH	O	9	P	O
O	O	O	1127	1136	regulates	regulate	B-VP	VBZ	O	0	ROOT	O
O	O	O	1137	1142	viral	viral	B-NP	JJ	O	14	NMOD	O
O	O	O	1143	1153	expression	expression	I-NP	NN	O	12	OBJ	O
O	O	O	1154	1157	and	and	O	CC	O	12	VMOD	O
O	O	O	1158	1160	is	be	B-VP	VBZ	O	12	VMOD	O
O	O	O	1161	1167	highly	highly	I-VP	RB	O	16	VMOD	O
O	O	O	1168	1178	attenuated	attenuate	I-VP	VBN	O	16	VC	O
O	O	O	1179	1181	in	in	B-PP	IN	O	18	VMOD	O
O	O	O	1182	1186	both	both	O	CC	O	26	NMOD	O
O	O	O	1187	1193	Jurkat	Jurkat	B-NP	NN	B-cell_line	26	NMOD	B-cell_line
O	O	O	1194	1197	and	and	I-NP	CC	O	26	NMOD	O
O	O	O	1198	1208	peripheral	peripheral	I-NP	JJ	B-cell_type	26	NMOD	B-cell_type
O	O	O	1209	1214	blood	blood	I-NP	NN	I-cell_type	26	NMOD	I-cell_type
O	O	O	1215	1226	mononuclear	mononuclear	I-NP	JJ	I-cell_type	26	NMOD	I-cell_type
O	O	O	1227	1232	cells	cell	I-NP	NNS	I-cell_type	19	PMOD	I-cell_type
O	O	O	1232	1233	.	.	O	.	O	12	P	O

O	O	O	1234	1236	We	We	B-NP	PRP	O	2	SUB	O
O	O	O	1237	1244	provide	provide	B-VP	VBP	O	0	ROOT	O
O	O	O	1245	1251	formal	formal	B-NP	JJ	O	4	NMOD	O
O	O	O	1252	1257	proof	proof	I-NP	NN	O	2	OBJ	O
O	O	O	1258	1262	that	that	B-SBAR	IN	O	4	NMOD	O
O	O	O	1263	1266	the	the	B-NP	DT	O	10	NMOD	O
O	O	O	1267	1277	phenotypic	phenotypic	I-NP	JJ	O	9	AMOD	O
O	O	O	1278	1281	and	and	I-NP	CC	O	9	AMOD	O
O	O	O	1282	1293	attenuating	attenuate	I-NP	VBG	O	10	NMOD	O
O	O	O	1294	1309	characteristics	characteristic	I-NP	NNS	O	17	SUB	O
O	O	O	1310	1312	of	of	B-PP	IN	O	10	NMOD	O
T6	B-Protein	B-Protein	1313	1320	IkappaB	IkappaB	B-NP	NN	B-protein	16	NMOD	B-protein
T6	I-Protein	I-Protein	1320	1321	-	-	B-NP	HYPH	O	16	NMOD	O
T6	I-Protein	I-Protein	1321	1329	alphaS32	alphaS32	I-NP	NN	B-protein	16	NMOD	B-protein
O	O	O	1329	1330	/	/	I-NP	SYM	I-protein	16	NMOD	I-protein
O	O	O	1330	1333	36A	36A	I-NP	NN	I-protein	11	PMOD	I-protein
O	O	O	1334	1340	permit	permit	B-VP	VBP	O	5	SBAR	O
O	O	O	1341	1344	its	its	B-NP	PRP$	O	20	NMOD	O
O	O	O	1345	1351	stable	stable	I-NP	JJ	O	20	NMOD	O
O	O	O	1352	1363	maintenance	maintenance	I-NP	NN	O	17	OBJ	O
O	O	O	1364	1366	in	in	B-PP	IN	O	17	VMOD	O
O	O	O	1367	1368	a	a	B-NP	DT	O	23	NMOD	O
O	O	O	1369	1373	live	live	I-NP	NN	O	21	PMOD	O
O	O	O	1373	1374	,	,	O	,	O	17	P	O
O	O	O	1375	1386	replicating	replicate	B-VP	VBG	O	17	VMOD	O
O	O	O	1387	1390	HIV	HIV	B-NP	NN	O	27	NMOD	O
O	O	O	1390	1391	-	-	B-NP	HYPH	O	25	OBJ	O
O	O	O	1391	1392	1	1	I-NP	CD	O	27	NMOD	O
O	O	O	1393	1400	despite	despite	B-PP	IN	O	25	VMOD	O
O	O	O	1401	1404	180	180	B-NP	CD	O	31	NMOD	O
O	O	O	1405	1409	days	day	I-NP	NNS	O	29	PMOD	O
O	O	O	1410	1412	of	of	B-PP	IN	O	31	NMOD	O
O	O	O	1413	1419	forced	force	B-NP	VBN	O	36	NMOD	O
O	O	O	1420	1422	ex	ex	I-NP	FW	O	35	AMOD	O
O	O	O	1423	1427	vivo	vivo	I-NP	FW	O	36	NMOD	O
O	O	O	1428	1437	passaging	passaging	I-NP	NN	O	32	PMOD	O
O	O	O	1438	1440	in	in	B-PP	IN	O	36	NMOD	O
O	O	O	1441	1447	tissue	tissue	B-NP	NN	B-cell_line	39	NMOD	B-cell_line
O	O	O	1448	1455	culture	culture	I-NP	NN	I-cell_line	37	PMOD	I-cell_line
O	O	O	1455	1456	.	.	O	.	O	2	P	O

O	O	O	1457	1459	As	As	B-SBAR	IN	O	20	VMOD	O
O	O	O	1460	1468	compared	compare	B-PP	VBN	O	1	SBAR	O
O	O	O	1469	1473	with	with	B-PP	IN	O	2	VMOD	O
O	O	O	1474	1479	other	other	B-NP	JJ	O	8	NMOD	O
T14	B-Entity	B-Entity	1480	1484	open	open	I-NP	JJ	B-DNA	8	NMOD	B-DNA
T14	I-Entity	I-Entity	1484	1485	-	-	I-NP	HYPH	I-DNA	8	NMOD	I-DNA
T14	I-Entity	I-Entity	1485	1492	reading	read	B-VP	VBG	I-DNA	8	NMOD	I-DNA
T14	I-Entity	I-Entity	1493	1499	frames	frame	B-NP	NNS	I-DNA	3	PMOD	I-DNA
O	O	O	1500	1508	embedded	embed	B-VP	VBN	O	8	NMOD	O
O	O	O	1509	1513	into	into	B-PP	IN	O	9	VMOD	O
T15	B-Entity	B-Entity	1514	1517	HIV	HIV	B-NP	NN	B-DNA	14	NMOD	B-DNA
T15	I-Entity	I-Entity	1517	1518	/	/	B-NP	SYM	I-DNA	14	NMOD	I-DNA
T15	I-Entity	I-Entity	1518	1521	SIV	SIV	I-NP	NN	I-DNA	14	NMOD	I-DNA
T15	I-Entity	I-Entity	1522	1528	genome	genome	I-NP	NN	I-DNA	10	PMOD	I-DNA
O	O	O	1528	1529	,	,	O	,	O	20	P	O
O	O	O	1530	1534	this	this	B-NP	DT	O	17	NMOD	O
O	O	O	1535	1541	degree	degree	I-NP	NN	O	20	SUB	O
O	O	O	1542	1544	of	of	B-PP	IN	O	17	NMOD	O
O	O	O	1545	1554	stability	stability	B-NP	NN	O	18	PMOD	O
O	O	O	1555	1557	is	be	B-VP	VBZ	O	0	ROOT	O
O	O	O	1558	1571	unprecedented	unprecedented	B-ADJP	JJ	O	20	PRD	O
O	O	O	1571	1572	.	.	O	.	O	20	P	O

O	O	O	1573	1577	Thus	Thus	B-ADVP	RB	O	8	VMOD	O
O	O	O	1577	1578	,	,	O	,	O	8	P	O
T7	B-Protein	B-Protein	1579	1586	IkappaB	IkappaB	B-NP	NN	B-protein	7	NMOD	B-protein
T7	I-Protein	I-Protein	1586	1587	-	-	I-NP	HYPH	O	7	NMOD	O
T7	I-Protein	I-Protein	1587	1595	alphaS32	alphaS32	I-NP	NN	B-protein	7	NMOD	B-protein
O	O	O	1595	1596	/	/	B-NP	SYM	I-protein	7	NMOD	I-protein
O	O	O	1596	1599	36A	36A	I-NP	NN	I-protein	8	SUB	I-protein
O	O	O	1600	1606	offers	offer	B-VP	VBZ	O	0	ROOT	O
O	O	O	1607	1612	proof	proof	B-NP	NN	O	8	OBJ	O
O	O	O	1612	1613	-	-	O	HYPH	O	9	P	O
O	O	O	1613	1615	of	of	B-PP	IN	O	9	NMOD	O
O	O	O	1615	1616	-	-	B-NP	HYPH	O	17	NMOD	O
O	O	O	1616	1625	principle	principle	I-NP	NN	O	17	NMOD	O
O	O	O	1626	1630	that	that	B-NP	IN	O	17	NMOD	O
O	O	O	1631	1644	artifactually	artifactually	B-NP	RB	O	16	AMOD	O
O	O	O	1645	1651	gained	gain	I-NP	VBN	O	17	NMOD	O
O	O	O	1652	1661	functions	function	I-NP	NNS	O	11	PMOD	O
O	O	O	1661	1662	,	,	O	,	O	8	P	O
O	O	O	1663	1667	when	when	B-ADVP	WRB	O	8	VMOD	O
O	O	O	1668	1672	used	use	B-VP	VBN	O	19	SBAR	O
O	O	O	1673	1675	to	to	B-VP	TO	O	22	VMOD	O
O	O	O	1676	1685	attenuate	attenuate	I-VP	VB	O	20	VMOD	O
O	O	O	1686	1689	the	the	B-NP	DT	O	24	NMOD	O
O	O	O	1690	1701	replication	replication	I-NP	NN	O	22	OBJ	O
O	O	O	1702	1704	of	of	B-PP	IN	O	24	NMOD	O
O	O	O	1705	1709	live	live	B-NP	JJ	O	27	NMOD	O
O	O	O	1710	1713	HIV	HIV	I-NP	NN	O	25	PMOD	O
O	O	O	1713	1714	-	-	B-NP	HYPH	O	24	P	O
O	O	O	1714	1715	1	1	I-NP	CD	O	24	NMOD	O
O	O	O	1715	1716	,	,	O	,	O	8	P	O
O	O	O	1717	1720	can	can	B-VP	MD	O	8	VMOD	O
O	O	O	1721	1723	be	be	I-VP	VB	O	31	VC	O
O	O	O	1724	1730	stable	stable	B-ADJP	JJ	O	32	PRD	O
O	O	O	1730	1731	.	.	O	.	O	8	P	O

O	O	O	1732	1737	These	These	B-NP	DT	O	2	NMOD	O
O	O	O	1738	1746	findings	finding	I-NP	NNS	O	3	SUB	O
O	O	O	1747	1757	illustrate	illustrate	B-VP	VBP	O	0	ROOT	O
O	O	O	1758	1762	gain	gain	B-NP	NN	O	5	NMOD	O
O	O	O	1762	1763	-	-	B-NP	HYPH	O	3	OBJ	O
O	O	O	1763	1765	of	of	B-PP	IN	O	5	NMOD	O
O	O	O	1765	1766	-	-	B-NP	HYPH	O	8	NMOD	O
O	O	O	1766	1774	function	function	I-NP	NN	O	6	PMOD	O
O	O	O	1775	1777	as	as	B-PP	IN	O	5	NMOD	O
O	O	O	1778	1779	a	a	B-NP	DT	O	12	NMOD	O
O	O	O	1780	1788	feasible	feasible	I-NP	JJ	O	12	NMOD	O
O	O	O	1789	1797	strategy	strategy	I-NP	NN	O	9	PMOD	O
O	O	O	1798	1801	for	for	B-PP	IN	O	12	NMOD	O
O	O	O	1802	1812	developing	develop	B-VP	VBG	O	13	PMOD	O
O	O	O	1813	1818	safer	safe	B-NP	JJR	O	19	NMOD	O
O	O	O	1819	1823	live	live	I-NP	NN	O	19	NMOD	O
O	O	O	1823	1824	-	-	B-NP	HYPH	O	19	NMOD	O
O	O	O	1824	1834	attenuated	attenuate	I-NP	VBN	O	19	NMOD	O
O	O	O	1835	1839	HIVs	HIV	I-NP	NNS	O	14	OBJ	O
O	O	O	1840	1842	to	to	B-VP	TO	O	21	VMOD	O
O	O	O	1843	1845	be	be	I-VP	VB	O	19	NMOD	O
O	O	O	1846	1852	tested	test	I-VP	VBN	O	21	VC	O
O	O	O	1853	1855	as	as	B-PP	IN	O	22	VMOD	O
O	O	O	1856	1866	candidates	candidate	B-NP	NNS	O	23	PMOD	O
O	O	O	1867	1870	for	for	B-PP	IN	O	24	NMOD	O
O	O	O	1871	1875	AIDS	AIDS	B-NP	NN	O	27	NMOD	O
O	O	O	1876	1883	vaccine	vaccine	I-NP	NN	O	25	PMOD	O
O	O	O	1883	1884	.	.	O	.	O	3	P	O
